Skip to Content

'
Mariana Chavez Mac Gregor, MD, MSC

Present Title & Affiliation

Primary Appointment

Assistant Professor, Tenure track, Department of Health Services Research, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2004 Netherlands Institute of Health and Sciences, Rotterdam, Netherlands, MSc, Clinical Epidemiology
2003 Universidad Nacional Autónoma de México, Facultad de Medicina, Mexico City, Mexico, MD, Medicine

Postgraduate Training

7/2008-6/2011 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2006-6/2008 Clinical Residency, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO
7/2005-6/2006 Clinical Internship, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO

Board Certifications

5/2016 Medical Oncology (Mexican Board of Oncology)
11/2011 Medical Oncology
2008 Internal Medicine

Experience/Service

Other Appointments/Responsibilities

Member, NCCN Foundation Young Investigator Award Review Comittee, 2016-present
Member, SWOG CCDR Database Observational Study Working Group, 2015-present
Member, ASCO Representative in the Consensus Guideline on margins for ductal carcinoma in situ cancer, ASCO/SSO/ASTRO, 2015-2016
Liaison Member, ASCO Quality of Care Committee, Alexandria, VA, 7/2014-present
Member, ASCO Guideline Methodology Subcommittee, Alexandria, VA, 7/2014-present
Member, ASCO Guideline Committee, Alexandria, VA, 5/2014-present
Member, Multidisciplinary Breast Cancer Tumor Board MDACC Cooper, Weekly Teleconference, 2014-present
Member, SWOG Cost-Effectiveness and Outcomes Committee, Portland, OR, 10/2013-present
Member, ASCO representative in the Consensus Guideline on margins for invasive breast cancer, SSO/ASTRO, 2013-2014
Member, National Breast Cancer Guideline Committee, Mexico, Mexico, 2012-present
Member, SWOG Breast Committee, Portland, OR, 2011-present
Member, SWOG Breast Committee Working Group, Portland, OR, 2011-present
Medicine Chief Resident, John Cochran VA Medical Center, St. Louis, MO, 6/2007-1/2008
Study Coordinator, Departamento de Oncología, Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Mexico, 8/2004-5/2005

Institutional Committee Activities

Member, Clinical Effectiveness Subcommittee (CE Subcommittee), 8/2015-present
Nomination Committee, Charles A. LeMaistre Lecture, 8/2015-present
Member, MD Anderson Cancer Center at Cooper (MDACCC) Relationship Committee, 2014-present
Member, Mexican American Cohort Internal Advisory Board, 2014-present
Member, Clinical Research Committee 3, 8/2008-8/2012

Honors and Awards

2015 Outstanding Scientific and Academic Collaboration on Breast Cancer - Triple Negative, Best of ASCO
2015 Young Investigator award, Multinational Association of Supportive Care in Cancer (MASCC)
2011 Achievement in Clinical Research Award, The Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
2011 ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2011 Young Investigator Award, SWOG
2010 Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, MD Anderson Cancer Center
2010 ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2010 Selected for participation at the AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, Colorado
2009 AACR Minority Scholar, Susan G. Komen for the Cure
2009 Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, MD Anderson Cancer Center
2009 ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2008 Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, MD Anderson Cancer Center
2008 Kipnis-Daughaday Teaching Award, Washington University School of Medicine
2006 Best Poster Award, Mentors in Medicine Research Grant Scientific Symposium. Washington University School of Medicine
2006 Clinical Scientist Training and Research Program, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO.
2004 NIHES Award, Erasmus University Rotterdam, University of Amsterdam, Utrecht University, University of Nijmegen, National Institute of Public Health and Environment, Netherlands Cancer Institute
2003 Merit-based Academic CONACYT Scholarship, The National Council for Science and Technology in Mexico
2002 Achievement Medical Student Award, Universidad Nacional Autónoma de México
2001 Academic Distinction, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico

Professional Memberships

American Association for Cancer Research
Associate Member, 2009-present
American Society of Clinical Oncology
Associate Member, 2008-present
Mexican Society of Senology
Member, 2001-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Cleeland C, von Moos R, Walker MS, Wang Y, Gao J, Chavez Mac Gregor M, Liede A, Arellano J, Balakumaran A, Qian Y. Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Support Care Cancer 24(8):3557-65, 8/2016. e-Pub 3/2016. PMID: 27022965.
2. Elting LS, Xu Y, Chavez Mac Gregor M, Giordano SH. Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. Support Care Cancer 24(6):2695-706, 6/2016. e-Pub 1/2016. PMID: 26797253.
3. Rosenstock AS, Lei X, Tripathy D, Hortobagyi GN, Giordano SH, Chavez Mac Gregor M. Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat 157(2):339-50, 6/2016. e-Pub 5/2016. PMID: 27146586.
4. Sanford RA, Lei X, Barcenas CH, Mittendorf EA, Caudle AS, Valero V, Tripathy D, Giordano SH, Chavez Mac Gregor M. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Ann Surg Oncol 23(5):1515-21, 5/2016. e-Pub 12/2015. PMID: 26678405.
5. Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez Mac Gregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Ann Surg Oncol. e-Pub 5/2016. PMID: 27216742.
6. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez Mac Gregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol 34(10):1072-8, 4/2016. e-Pub 1/2016. PMID: 26811528.
7. Chaudry M, Banchs J, Chavez Mac Gregor M. Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker? Biomark Med 10(3):315-28, 3/2016. e-Pub 2/2016. PMID: 26860187.
8. Chavez Mac Gregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. JAMA Oncol 2(3):322-9, 3/2016. PMID: 26659132.
9. Chavez Mac Gregor M, Giordano SH. Randomized Clinical Trials and Observational Studies: Is There a Battle? J Clin Oncol 34(8):772-3, 3/2016. e-Pub 1/2016. PMID: 26786920.
10. Mittendorf EA, Vila J, Tucker SL, Chavez Mac Gregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. e-Pub 3/2016. PMID: 26986538.
11. Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez Mac Gregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist 21(1):21-7, 1/2016. e-Pub 12/2015. PMCID: PMC4709200.
12. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez Mac Gregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol 144(5):713-21, 11/2015. PMID: 26486734.
13. Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez Mac Gregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 153(2):417-23, 9/2015. e-Pub 8/2015. PMID: 26272743.
14. Bambhroliya A, Chavez Mac Gregor M, Brewster AM. Barriers to the Use of Breast Cancer Risk Reduction Therapies. J Natl Compr Canc Netw 13(7):927-35, 7/2015. PMID: 26150584.
15. Chavez Mac Gregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, Hortobagyi GN, Giordano SH. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol 33(19):2176-83, 7/2015. PMID: 25964256.
16. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez Mac Gregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):407-16, 7/2015. PMCID: PMC4492876.
17. Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez Mac Gregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment as a Tool for Survival in Patients with Breast Cancer and Brain Metastases. J Clin Oncol 33(20):2239-45, 7/2015. PMID: 25987700.
18. Parinyanitikul N, Lei X, Chavez Mac Gregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clin Breast Cancer 15(2):153-60, 4/2015. PMID: 25454687.
19. Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez Mac Gregor M. Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer 112(4):630-5, 2/2015. PMID: 25584488.
20. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez Mac Gregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget 6(5):2604-14, 2/2015. PMID: 25605252.
21. Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez MacGregor M, Yi M, Hunt KK, Strom EA. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol 22(1):90-5, 1/2015. PMID: 25249256.
22. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez Mac Gregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer 6(4):310-8, 2015. PMCID: PMC4349870.
23. Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez Mac Gregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the American college of surgeon's oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol 21(8):2468-73, 8/2014. PMID: 24841348.
24. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez Mac Gregor M, Freedman G, Houssami N, Johnson PL, Morrow M, Society of Surgical Oncology, American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. J Clin Oncol 32(14):1507-15, 5/2014. PMID: 24516019.
25. Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez Mac Gregor M. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735-44, 3/2014. PMCID: PMC3940536.
26. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez Mac Gregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Ann Surg Oncol 21(3):704-16, 3/2014. PMID: 24515565.
27. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez Mac Gregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Int J Radiat Oncol Biol Phys 88(3):553-64, 3/2014. PMID: 24521674.
28. Chavez Mac Gregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 23(2):316-23, 2/2014. PMCID: PMC3946290.
29. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez Mac Gregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25(2):384-91, 2014. PMID: 24351399.
30. Shen MC, Massarweh NN, Lari SA, Vaporciyan AA, Selber JC, Mittendorf EA, Chavez Mac Gregor M, Smith BD, Kuerer HM. Clinical Course of Breast Cancer Patients with Isolated Sternal and Full-Thickness Chest Wall Recurrences Treated With and Without Radical Surgery. Ann Surg Oncol 20(13):4153-60, 12/2013. PMID: 23959054.
31. Chavez Mac Gregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33):4222-8, 11/2013. PMCID: PMC3821011.
32. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez Mac Gregor M, Smart M, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13(5):378-84, 10/2013. PMCID: PMC3839051.
33. Chae YK, Hu MI, Katz RL, Chavez Mac Gregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol 31(23):e398-400, 8/2013. PMID: 23796991.
34. Chavez Mac Gregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer 119(9):1611-7, 5/2013. PMID: 23341341.
35. Gonzalez-Angulo AM, Liu S, Chen H, Chavez Mac Gregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol 24(4):909-16, 4/2013. PMCID: PMC3603436.
36. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez Mac Gregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 1/2013. PMCID: PMC3461089.
37. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez Mac Gregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus 2:409, 2013. PMCID: PMC3797914.
38. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez Mac Gregor M. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. J Cancer 4(7):549-56, 2013. PMCID: PMC3753529.
39. Lynch SP, Lei X, Chavez Mac Gregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063-9, 12/2012. PMCID: PMC3501230.
40. Raghav KP, Wang W, Liu S, Chavez Mac Gregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 4/2012. PMID: 22374333.
41. Raghav KP, Hernandez-Aya LF, Lei X, Chavez Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 3/2012. PMCID: PMC3217101.
42. Chavez Mac Gregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 118(2):326-32, 1/2012. PMCID: PMC3158806.
43. Chavez Mac Gregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YC, Giordano SH. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol 22(11):2394-402, 11/2011. PMID: 21393379.
44. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez Mac Gregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clin Breast Cancer 11(5):325-31, 10/2011. PMID: 21764391.
45. Chavez Mac Gregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: A Surveillance, Epidemiology, and End Results-Medicare Study. Cancer 117(16):3641-9, 8/2011. PMID: 21656514.
46. Melhem-Bertrandt A, Chavez Mac Gregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645-52, 7/2011. PMCID: PMC3139371.
47. Hernandez-Aya LF, Chavez Mac Gregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 7/2011. PMCID: PMC3139370.
48. Chavez Mac Gregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17):4168-77, 9/2010. PMCID: PMC2954673.
49. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez Mac Gregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11(5):421-8, 5/2010. PMID: 20362507.
50. Chavez Mac Gregor M, van Gils CH, van der Schouw YT, Monninkhof E, van Noord PA, Peeters PH. Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. Breast Cancer Res Treat 108(1):101-12, 3/2008. PMCID: PMC2244694.
51. Ruvalcaba-Limón E, Robles-Vidal C, Poitevin-Chacón A, Chavez Mac Gregor M, Gamboa-Vignolle C, Vilar-Compte D. Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: A case-control analysis. Breast Cancer Res Treat 95(2):147-52, 1/2006. PMID: 16319989.
52. Chavez Mac Gregor M, Aviles-Salas A, Green D, Fuentes-Alburo A, Gómez-Ruiz C, Aguayo A. Angiogenesis in the bone marrow of patients with breast cancer. Clin Cancer Res 11(15):5396-400, 8/2005. PMID: 16061853.
53. Chavez Mac Gregor M, Elias SG, Onland-Moret NC, van der Schouw YT, Van Gils CH, Monninkhof E, Grobbee DE, Peeters PH. Postmenopausal breast cancer risk and cumulative number of menstrual cycles. Cancer Epidemiol Biomarkers Prev 14(4):799-804, 4/2005. PMID: 15824146.
54. Vidal-Millan S, Zeichner-Gancz I, Flores-Estrada D, Vela-Rodríguez BE, Vazquez-López MI, Robles-Vidal CD, Ramirez-Ugalde MT, Chavez Mac Gregor M. A descriptive study of second primary malignancies associated to breast cancer in a Mexican Hispanic population. Med Oncol 22(1):17-22, 2005. PMID: 15750192.

Invited Articles

1. Brewster AM, Chavez Mac Gregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 15(13):e625-34, 12/2014. PMID: 25456381.
2. Chavez Mac Gregor M, Gonzalez-Angulo AM. Breast cancer in 2012: New drugs, new knowledge, new targets. Nat Rev Clin Oncol 10(2):75-6, 2/2013. PMID: 23296111.
3. Gagliato D, Chavez Mac Gregor M. Adjuvant bisphosphonates in breast cancer: has the time come? Breast Cancer Manage 2(4):327-337, 2013.
4. Chavez Mac Gregor M, Gonzalez-Angulo AM. Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs 21(12):1835-43, 12/2012. PMID: 22994502.
5. Chavez Mac Gregor M, González-Angulo AM. Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol 12(7):461-7, 7/2010. PMID: 20615822.
6. Chavez Mac Gregor M, Gonzalez-Angulo AM. HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group? Clin Adv Hematol Oncol 7(9):591-8, 9/2009. PMID: 20020671.
7. Ochoa-Carrillo FJ, Chavez Mac Gregor M, Green-Renner D, Green-Schneeweiss L. [Paraneoplastic syndromes. Associated with lung cancer]. Cir Cir 71(2):150-61, Mar-Apr, 3/2003. PMID: 19764144.
8. Chavez Mac Gregor M, Ochoa-Carrillo F, Fuentes-Alburo A. Neurological Paraneoplastic Syndromes. Rev Inst Nal Cancerol 46(4):281-289, 2000.

Editorials

1. Chavez Mac Gregor M, Valero V. Commentary on: Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative interventional cohort study of 13722 women. Breast Diseases: A Year Book Quarterly. In Press.
2. Chavez Mac Gregor M, Hortobagyi GN. Commentary on: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data. Breast Diseases: A Year Book Quarterly 22:262-263, 2011.
3. Chavez Mac Gregor M, Valero V. Commentary on: Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with reagard to disease course and intervening systemic therapy. Breast Diseases: A Year Book Quarterly 22:270-271, 2011.
4. Chavez Mac Gregor M. Bone Therapy in Breast Cancer: Why, when and what's next? The Breast Cancer Report 2(1), 2010.
5. Chavez Mac Gregor M, Gonzalez-Angulo AM. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Breast Diseases: A Year Book Quarterly 21(2):142-3, 2010.
6. Chavez Mac Gregor M, Weilbaecher K, Aft R. Bone marrow micrometastases: Is there a role for bisphosphonates? Breast Diseases: A Year Book Quarterly 19(4), 2009.
7. Chavez Mac Gregor M, Gonzalez-Angulo AM. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumors. Br J Cancer 100:680-83, 2009.

Abstracts

1. Alvarez RH, Koenig KB, Ensor JE, Ibrahim NK, Chavez Mac Gregor M, Litton JK, Schwartz Gomez JK, Cyriac A, Krishnamurty S, Caudle AS, Shaitelman SF, Whitman GJ, Booser DJ, Reuben JM, Valero V. A randomized phase II neoadjuvant (NACT) study of sequential eribulin followed by FAC/FEC-regimen compared to sequential paclitaxel followed by FAC/FEC-regimen in patients (pts) with operable breast cancer not overexpressing HER-2. Poster Session 1: Treatment: Neoadjuvant Chemotherapy. SABCS 2015 (#P1-14-04), 12/2015.
2. Mittendorf EA, Vila J, Tucker SL, Chavez Mac Gregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. Bioscore: A novel staging system for breast cancer patients receiving neoadjuvant chemotherapy. Poster Session 5: Prognostic and Predictive Factors: Prognostic and Predictive Factors -- Other. SABCS 2015 (#P5-08-04), 12/2015.
3. Chavez MacGregor M, Clark CA, Lichetensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among breast cancer patients: A population-based study. Poster Session 1: Treatment: Adjuvant Chemotherapy. SABCS 2015 (#P1-12-07), 12/2015.
4. Chavez Mac Gregor M, Barlow WE, Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Gralow J, Lew DL, Hortobagyi GN. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). Session Info: Ongoing Clinical Trials: Ongoing Trials -- Targeted Therapies. SABCS 2015 (#OT1-03-11), 12/2015.
5. Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Wheler JJ, Valero V, Albarracin C, Litton J, Chavez Mac Gregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder S. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. Poster Session 3: Treatment: Novel Targets and Targeted Agents. SABCS 2015 (#P3-14-02), 12/2015.
6. Bardia A, Modi S, Oliveira M, Campone M, Ma B, Dirix L, Weise A, Nardi L, Zhang V, Bhansali SG, Hewes B, Chavez Mac Gregor M. Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer. Poster Session 6: Treatment: New Drugs and Treatment Strategies. SABCS 2015 (#P6-13-01), 12/2015.
7. Chavez Mac Gregor M, Zhigang D, Hwang J, Giordano SH. Hepatitis B virus screening among Rituximab-treated patients. Poster Session: Haematological Malignancies. 18th ECCO - 40th ESMO European Cancer Congress (#3229), 9/2015.
8. Chavez Mac Gregor M, Lei X, Tripathy D, Rosentock A, Giordano SH. Short-term mortality in older (>66) patients with early stage breast cancer treated with adjuvant chemotherapy. Poster Session: Cancer in the Elderly. 18th ECCO - 40th ESMO European Cancer Congress (#1329), 9/2015.
9. Chavez Mac Gregor M, He W, Zhao H, Elting L, Giordano S. Antiemesis Prophylaxis among breast cancer (BC) patients receiving anthracycline-based chemotherapy: A population-based study. (Presented as an oral session at the 2015 Annual Meeting of the Multinational Association of Supportive Care in Cancer. Awarded Young Investigator Award). Support Care Cancer 2015; 23(s1) Journal of Supportive Care (#11-02-O) (#11-02-O), 6/2015.
10. Vila J, Bassett R, Mittendorf E, Bedrosian I, Shaitelman S, Stauder M, Chavez Mac Gregor M, Litton J, Yang W, Huo L, Kuerer H, Hunt K, Caudle A. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients. J Clin Oncol 33 (#1034), 5/2015.
11. Chavez Mac Gregor M, He W, Zhao H, Elting L, Giordano S. Antiemesis prophylaxis among breast cancer (BC) patients receiving highly emetogenic chemotherapy. J Clin Oncol 33 (#e12005), 5/2015.
12. Basho R, Gagliato D, Ueno N, Alvarez R, Wathoo C, Chen H, Wei C, Sahin A, Roy-Chowdhuri S, Moulder S, Chavez Mac Gregor M, Litton J, Valero V, Luthra R, Shaw K, Mendelsohn J, Mills G, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. J Clin Oncol 33 (#1524), 5/2015.
13. DU FL, Fujii T, Davis D, Wu W, Jackson S, Chavez Mac Gregor M, Barcenas C, Murray J, Valero V, Tripathy D, Reuben J, Ueno N. EpCAM-independent isolation of EMT- circulating tumor cells in patients with primary breast cancer who receive primary systemic therapy. J Clin Oncol 33 (#11034), 5/2015.
14. Barcenas C, Sinha A, Hortobagyi G, Valero V, Ueno N, Giordano S, Chavez Mac Gregor, Brewster A, Lucci A, Tripathy D. Hormonal treatment (HT) and late recurrence in early-stage breast cancer (BC) patients. J Clin Oncol 33 (#563), 5/2015.
15. Sanford R, Lei X, Barcenas C, Mittendorf E, Caudle A, Valero V, Tripathy D, Giordano S, Chavez Mac Gregor M. Impact of neoadjuvant chemotherapy to surgery interval on survival outcomes in breast cancer patients. J Clin Oncol 33 (#1063), 5/2015.
16. Chavez Mac Gregor M, Barlow W, Gonzalez-Angulo A, Rastogi P, Mamounas E, Ganz P, Schott A, Paik S, Lew D, Bandos H, Hortobagyi G. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). J Clin Oncol 33 (#TPS637), 5/2015.
17. Alvarez RH, Chavez Mac Gregor M, Ensor J, Murray JL, Koenig K, Krishnamurty S, Lucci A, Babiera GV, Woodward W, Whitman GJ, Jackson SA, Shi M, Culver K, Reuben JL, Ueno NT, Valero V. A Phase II Study of Dovitinib as Salvage Therapy in Patients with Stage IV Inflammatory Breast Cancer HER2-Negative with Local or Distant Relapse. Ongoing Clinical Trials 1: Targeted Therapies (OT1-1-15). 2014 San Antonio Breast Cancer Symposium, 12/2014.
18. Alvarez RH, Ibrahim NK, Ensor J, Koenig K, Chavez Mac Gregor M, Gonzalez-Angulo AM, Schwartz Gomez J, Madrigal AG, Krishnamurty S, Caudle AS, Shaitelman SF, Whitman GJ, Murray LJ, Booser DJ, Cox D, Reuben JM, Valero V. A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-Regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Patients with Operable Breast Cancer not Overexpressing HER-2. Ongoing Clinical Trials 2: Chemotherapies (OT2-2-04). 2014 San Antonio Breast Cancer Symposium, 12/2014.
19. Rosentstock AS, Giordano SH, Niu J, Zhao H, Wolff AC, Buchholz TA, Chavez Mac Gregor M. AML and MDS after Adjuvant Chemotherapy: A Population Based Study among Older Breast Cancer Patients. Poster Session: Adjuvant Chemotherapy (P3-09-04). 2014 San Antonio Breast Cancer Symposium, 12/2014.
20. Chavez Mac Gregor M, Niu J, Smith B, Zhao H, Buchholz TA, Giordano SH. Oncotype Dx Use and its Relationship with Chemotherapy Administration in the General Population. Poster Session: Epidemiology-Population Studies (P3-07-05). 2014 San Antonio Breast Cancer Symposium, 12/2014.
21. Le Du F, Duose DY, Dettman EJ, Summer JA, Chavez Mac Gregor M, Barcenas CH, Brewster AM, Ricardo AH, Valero V, Gonzalez-Angulo AM, Reuben JM, Ueno NT. Predictive Impact of Circulating Tumor Cells with an Epithelial-To-Mesenchymal Transition Phenotype in Patients with Primary Breast Cancer Treated with Primary Systemic Therapy. Poster Session: Circulating Tumor Cells (P4-01-10). 2014 San Antonio Breast Cancer Symposium, 12/2014.
22. Chavez Mac Gregor M, Parinyanitikul N, Mittendorf EA, Lei X, Zhang H, Buzdar A, Hunt K, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Effect of Adjuvant Trastuzumab (T) Among Patients Treated with Neoadjuvant T-based Chemotherapy. J Clin Oncol 32(5) (#644), 6/2014.
23. Bardia A, Modi S, Chavez Mac Gregor M, Kittaneh M, Marino AJ, Matano A, Bhansali S, Hewes B, Cortes J. Phase Ib/II Study of LEE011, Everolimus, and Exemestane in Postmenopausal Women with ER+/HER2-Metastatic Breast Cancer. J Clin Oncol 32(5) (#535), 6/2014.
24. Kogawa T, Fouad TM, Wei C, El-Zein RA, Masuda H, Chavez Mac Gregor M, Melhem-Bertrandt A, Litton JK, Brewster AM, Alvarez RH, Hortobagyi GN, Vicente V, Ueno NT, Theriault RL. Association between body mass index change during neoadjuvant chemotherapy and pathologic complete response and overall survival in patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer. Proceedings from 2013 San Antonio Breast Cancer Symposium, 12/2013.
25. Masuda H, Chavez Mac Gregor M, Liu DD, Alvarez RH, Krishnamurthy S, Lucci A, Woodward W, Gildy B, Mittendorf EA, DeSnyder SM, Shen Y, Willey JS, Hortobagyi GN, Valero V, Ueno NT. Predictors of poor clinical outcome among patients with inflammatory breast cancer (IBC) who did and did not achieve pathological complete response (pCR) after neoadjuvant systemic chemotherapy. Proceedings from 2013 San Antonio Breast Cancer Symposium, 12/2013.
26. Chavez Mac Gregor M, Lei X, Litton JK, Melhem-Bertrand A, Giordano SH, Masuda H, Ueno N, Gabriel HN, Valero V. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy. Proceedings from 2013 San Antonio Breast Cancer Symposium, 12/2013.
27. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Arun B, Chavez Mac Gregor M, Alvarez RH, Lucci A, Krishnamurthy S, Hortobagyi GN, Valero V, Ueno NT. Survival difference between patients with metastatic inflammatory and non-inflammatory breast cancer. Proceedings from 2013 San Antonio Breast Cancer Symposium, 12/2013.
28. Pusztai L, Mattair D, Ueno NT, Valero V, Moulder SL, Murray JL, Alvarez RH, Chavez Mac Gregor M, Santiago L, Avritscher R, Sahin AA, Hortobagyi GN, Symmand WF, Meric-Bernstam F, Burton EM, Gonzalez-Angulo AM. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. J Clin Oncol(31) (#532), 2013.
29. Chavez Mac Gregor M, Zhang N, Niu J, Elting LS, Buchholz TA, Valero V, Giordano SH. Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older breast cancer patients. JClin Oncol 31 (#6330), 2013.
30. Chavez Mac Gregor M, Parinyanitikul N, Lei X, Mittendorf E, Litton JK, Woodward W, Zhang A; Gonzalez-Angulo AM. Changes in breast cancer subtype between primary tumor and residual disease after neoadjuvant systemic chemotherapy. Proceedings from European CanCer Organization (ECCO) – ESMO Meeting (#2065), 2013.
31. Gagliato DD, Gonzalez-Angulo AM, Aiudong L, Giordano SH, Theriault RL, Valero V, Hortobagyi GN, Chavez Mac Gregor M. Impact of delaying initiation of adjuvant chemotherapy in breast cancer patients. J Clin Oncol 31 (#1022), 2013.
32. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez Mac Gregor M, Smart ML, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple-receptor negative breast cancer. J Clin Oncol (#e12002), 2013.
33. Chavez Mac Gregor M, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA, Schott A, Paik S, Lew D, Bandos H, Hortobagyi GN. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy with or without one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-neu-negative breast cancer: SWOG/NSABP S1207. J Clin Oncol 31 (#TPS657), 2013.
34. Kogawa T, Fouad T, Liu D, Shen Y, Masuda H, Chavez Mac Gregor M, Alvarez RH, Valero V, Hortobagyi GN, Ueno NT. Role of HER2 FISH ratios in predicting pathological complete response (pCR) to neoadjuvant systemic chemotherapy with trastuzumab in patients with inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer. Proceeding from European CanCer Organization (ECCO) – ESMO Meeting (#1910), 2013.
35. Young Kwang C, Brown EN, Lei X. Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez Mac Gregor M. ACE inhibitors and angiotensin receptor blockers use and breast cancer outcomes in patients treated with neoadjuvant systemic chemotherapy. J Clin Oncol 30 (#537), 6/2012.
36. Lynch SP, Lei X, Chavez Mac Gregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang H, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Breast cancer multifocality-multicentricity and survival outcomes. J Clin Oncol 30 (#1104), 6/2012.
37. Chavez Mac Gregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting LS, Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older breast cancer patients. J Clin Oncol 30 (#600), 6/2012.
38. Chavez Mac Gregor M, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA, Schott AF, Paik S, Lew DL, Bandos H, Hortobagyi GN. A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-(HR) positive and HER2-negative breast cancer: SWOG S1207. Cancer Res 72(24):570s (#OT2-2-04), 2012.
39. Chavez Mac Gregor M, Lei X, Giordano SH, Valero V, Esteva F, Mittendorf EA, Gonzalez-Angulo AM, Hortobagyi GN. Predictors of long-term survival in a large cohort of patients with HER2-positive metastatic breast cancer. Cancer Res 72(24), 2012.
40. Raghav KP, Wang W, Liu S, Chavez Mac Gregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blimenschein GR, Gonzalez-Angulo AM. Expressions of c-met and phospho c-met in breast cancer by subtype and its impact on survival outcomes. Cancer Res 71(24) (#P4-09-09), 12/2011.
41. Chavez Mac Gregor M, Clarke CA, Lichtensztajn DY, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: A California cancer registry (ccr)-population based study. Cancer Res 71(24) (#P4-19-01), 12/2011.
42. Chavez Mac Gregor M, Liu S, Chen H, Do K, Pusztai L, Symmans WF, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Relationship between differences in RNA or protein expression and the effects of race/ethnicity on breast cancer outcomes. 2011 Breast Cancer Symposium (#157), 10/2011.
43. Raghav KPS, Hernandez-Aya LF, Lei X, Chavez Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin AA, Do K, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen and progesterone-receptor expression on survival outcomes in breast cancer previously classified as triple-negative breast cancers. J Clin Oncol 29(15s):85s (#1023), 6/2011.
44. Chavez Mac Gregor M, Lei X, Litton JK, Melhem A, Mittendorf EA, Meric-Berstam F, Sahin AA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy. J Clin Oncol (#1036), 6/2011.
45. Moulder S, Moroney J, Wheler J, Chavez Mac Gregor M, Helgason T, Booser D, Albarracin C, Morrow P, Koenig K, Kurzrock R. Responses to liposomal doxorubicin, bevacizumab and temsirolimus in patients with metastatic metaplastic breast cancer: implications for stem cell research in breast cancer. Annals of Oncology 22(2):55 (#119P), 5/2011.
46. Chavez Mac Gregor M, Brown EN, Lei X, Hsu L, Meric-Bernstam F, Litton JK, Mittendorf EA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Cancer Res 70(24s) (#P1-11-22), 2010.
47. Litton JK, Chen H, Mittendorf EA, Meric-Bernstam F, Chavez Mac Gregor M, Woodward WA, Sahin A, Theriault RL, Hortobagyi GN, Gonzalez-Angulo AM. Outcome differences in tumors < 1cm by age and breast cancer subtype. J Clin Oncol (#580), 2010.
48. Chavez Mac Gregor M, Hubbard R, Meric-Bernstam F, Shinde SS, Litton JK, Woodard WA, Valero V, Hortobagyi GN, Symmans WF, Gonzalez-Angulo AM. Residual cancer burden (RCB) in breast cancer patients treated with taxane and anthracycline-based neoadjuvant chemotherapy: The effect of race. J Clin Oncol 28(15s) (#607), 2010.
49. Chavez Mac Gregor M, Zhao H, Hortobagyi GN, Giordano SH. Risk factors and incidence of thromboembolic events (TEE) in older patients after the diagnosis of breast cancer. Proc of the 5th Inter-American Breast Cancer Conference (#39), 2010.
50. Chavez Mac Gregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YCT, Giordano SH. Thromboembolic events in male breast cancer patients: A SEER-Medicare study. Proc of the Am Soc of Clin Oncol 2010 Breast Cancer Symposium (#183), 2010.
51. Guarneri V, Chavez Mac Gregor M, Hsu L, Symmans WF, Litton JL, Mittendorf EA, Conte PF, Hortobagyi GN, Gonzalez-Angulo AM. Use of ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. J Clin Oncol (#621), 2010.
52. Chavez Mac Gregor M, Vranas P, Lara JM, Jackson SA, Willey JS, Hsu L, Ueno NT, Andreopoulou E, Valero V, Lucci A, Buzdar AU, Buchholz D, Hortobagyi GN, Cristofanilli M. Clinical outcomes in two different cohorts of patients with inflammatory breast cancer (IBC) treated at the MD Anderson Cancer Center: The experience of the Morgan Welch IBC Research Program and Clinic. Cancer Res (#5119), 2009.
53. Chavez Mac Gregor M, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin stimulating agents (ESAs) in patients with metastatic breast cancer: A surveillance, epidemiology, and end results (SEER)-medicare study. J Clin Oncol 27(15s) (#1034), 2009.
54. Chavez Mac Gregor M, Litton J, Huiquin C, Meric-Bernstam F, Hudis CA, Wolff A, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo A. Race and pathological complete response (pCR) in breast cancer patients receiving anthracycline and taxane-based neoadjuvant chemotherapy. 2009 Breast Cancer Symposium (#09-AB-40116-ASCOBCS), 2009.
55. Chavez Mac Gregor M, Fang S, Zhao H, Hortobagyi GN, Giordano SH. Thromboembolic events in patient with breast cancer: A population based study. Caner Res 69(24):609s (#2053), 2009.
56. Aft R, Watson M, Ylagan L, Chavez Mac Gregor M, Trinkaus K, Zhai J, Naughton M, Weilbaecher K. Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. J Clin Oncol (#1021), 2008.
57. Aft R, Chavez Mac Gregor M, Trinkaus K, Naughton M, Weilbaecher K. Effect of zoledronic acid on bone loss in women undergoing chemotherapy for breast cancer. Breast Cancer Res Treat (#505), 2007.
58. Green D, Chavez Mac Gregor M, Sasa-Sanchez R, Andraca R, Enriquez L, Leon E, Ponce de Leon S. Fosfomycin prevents cisplatin-induced ototoxicity: Results of a randomized, double blind, placebo controlled trial. J Clin Oncol (#9041), 2007.
59. Chavez Mac Gregor M. Early procedural and late complications of percutaneous closure of patent foramen ovale with AGA amplatzer septal occluder. Proceedings of the Society for Cardiovascular Angiography and Interventions, 2006.
60. Chavez Mac Gregor M. Impact of zoledronic acid on chemotherapy-induced bone loss in women with locally advanced breast cancer. Proceedings of the Mentors in Medicine Research Grant Scientific Symposium, 2006.
61. Green D, Meza-Junco J, Arce C, Chavez Mac Gregor M, de la Pena R, Sotomayor M, Gabilondo F. Phase-II trial of thalidomide for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol (#4761), 2005.
62. Chavez Mac Gregor M. Breast cancer risk and cumulative number of menstrual cycles. Proceedings of the 25th WEON meeting, Epidemiology, 2004.
63. Chavez Mac Gregor M. Angiogensis and cell proliferation markers in cervical adenocarcinoma. Int J Gyn Obs 83:33, 2003.
64. Chavez Mac Gregor M. Angiogensis and cell proliferation markers in cervical adenocarcinoma. Modern Path 16(1):205, 2003.
65. Chavez Mac Gregor M. Breast cancer screening: How much do our women know?. Proceedings of the 2nd Congress of the World Society of Breast Health, 2003.
66. Chavez Mac Gregor M. CD 34 expression in the bone marrow of patients with breast cancer. Proceedings of the 2nd Congress of the World Society of Breast Health, 2003.
67. Chavez Mac Gregor M. Effect of gene e6wt and e-var2 of human papilloma virus 18 and the role of steroid hormones on vascular endothelial growth factor in mcf-7 cell line. Proceedings of the XIII International Congress on Anti Cancer Treatment, 2003.
68. Chavez Mac Gregor M, Aviles-Salas A, Fuentes-Alburo A, Cantu de Leon D, Gomez-Ruiz C, Aguayo A. Evidence of increased angiogenesis in the bone marrow (BM) of patients with breast cancer (BC). Proc Am Soc Clin Oncol (#170), 2003.
69. Chavez Mac Gregor M. Expression of CD 34 in cervical adenocarcinoma. Proceedings of the XIII Internantional Congress on Anti Cancer Treatment, 2003.
70. Chavez Mac Gregor M. Forequarter amputation for palliation: Is it worthwhile?. Ann Surg Oncol 10(1):S35, 2003.
71. Chavez Mac Gregor M. Male breast cancer at the national cancer institute in Mexico: 21 year experience. Proceedings of the XIII International Congress on Anti Cancer Treatment, 2003.
72. Chavez Mac Gregor M. Mastalgia: Comparison between three regimens of treatment. Proceeding of the 2nd Congress of the World Society of Breast Health, 2003.
73. Chavez Mac Gregor M. Pathologic response in locally advanced breast cancer patients treated with concurrent chemoradiation: evaluation of two drug schemes. Proceeding of the XIII International Congress on Anti Cancer Treatment, 2003.
74. Chavez Mac Gregor M. Anthropological analysis of pain in breast cancer patients. Proceedings of the XVIII Annual Meeting of the National Institute of Cancer of Mexico, 2001.
75. Chavez Mac Gregor M. Early detection of breast cancer: who is responsible?. Proceedings of the 23rd San Antonio Breast Cancer Symposium, 2000.
76. Chavez Mac Gregor M. Management of breast cancer by physicians specialized in areas other than oncology. Rev Inst Nal Cancerol 46(2):120, 2000.
77. Chavez Mac Gregor M. Neurologic paraneoplastic syndromes at the national institute of neurology in Mexico. Rev Inst Nal Cancerol 46(2):121, 2000.
78. Chavez Mac Gregor M. Pilot study: effectiveness of emotional management with an analogical rule in cancer patients. Rev Inst Nal Cancerol 46(2):120, 2000.
79. Chavez Mac Gregor M. Analysis of specific antibodies in placenta and in fetal blood. Proceedings of the XVIII Panamerican Congress in Pediatric Infectology, 1998.

Book Chapters

1. Chavez Mac Gregor M, Gonzalez-Angulo AM, Hortobagyi GN. Breast Cancer Medical Therapy in High-Resource Countries. In: World Breast Cancer 2012. Ed(s) Boyle P, Autier P, Adebamowo C, Anderson B, Pinillos Aston L, Badwe RA, Yamaguchi N. International Prevention Research Institute: France, 435-47, 2012. ISBN: 978-2-9539268-1-1.
2. Chavez Mac Gregor M, Valero V, Hortobagyi GN. Locally advanced breast cancer. In: Advanced Therapy of Breast Diseases, 3rd. Ed(s) Babiera GV, Skoracki RJ, Esteva FJ, 855-876, 2012.
3. Chavez Mac Gregor M, Gonzalez-Angulo AM. Metastatic Breast Cancer. In: Clinical Decision Support: Oncology. Ed(s) Johnson D, Benz EJ, Gerber D, and LaCasce, Digital Program, 2012.
4. Chavez Mac Gregor M, Hortobagyi GN. Metastatic breast cancer: A curable disease? In: Breast Cancer Today. Ed(s) J Diaz, A Ruibal, A Tejerina. FEMA: Spain, 373-90, 2012. ISBN: 978-84-939918-4-5.
5. Chavez Mac Gregor M, Valero V. Metastatic breast cancer. In: The MD Anderson Manual of Medical Oncology, 679-710, 2011.
6. Chavez Mac Gregor M, Wildes TM. Breast cancer. In: Hematology and Oncology Subspecialty Consult, The Washington Manual Subspecialty Consult Series, 2nd, 189-203, 2008.

Letters to the Editor

1. Litton J, Buzdar A, Chavez-MacGregor M, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet 381(9883):2077-8, 6/2013. PMID: 23769223.
 

Other

1. Digital Program. Chavez Mac Gregor M, Gonzalez-Angulo AM.Metastatic Breast Cancer, in Clinical Decision Support: Oncology, edited by Johnson D, Benz EJ, Gerber D, and LaCasce A. 2012. Decision Support in Medicine, LLC. Wilmington, DE. .
2. Consensus Guideline. Quinta Revisión. Consenso Mexicano sobre diagnóstico y tratamiento del Cáncer Mamario. Colima, Elsevier. Mexico. 2013.
3. Consensus Guideline. Sexta Revisión. Consenso Mexicano sobre diagnóstico y tratamiento del Cáncer Mamario. Colima, Elsevier. Mexico. 2015.

Last updated: 7/11/2016